Mazdutide: GLP-1/Glucagon Dual Agonist in Late-Stage Trials (2026 Update)

Mazdutide is one of the more underdiscussed compounds in the late-stage GLP-1-class pipeline. Co-developed by Innovent Biologics and Eli Lilly, it is a dual GLP-1 and glucagon receptor agonist — the same mechanistic strategy as survodutide but a different molecule, different developer, and different clinical program. Mazdutide has received Chinese regulatory approval for chronic weight management on the basis of phase 3 readouts in Chinese populations and is progressing toward US FDA submission.

This post covers what mazdutide is, why GLP-1/glucagon dual agonism is a distinct mechanistic strategy, what trials have shown, where the US regulatory state sits as of May 2026, and what mazdutide approval would mean for the post-2027 prescribing landscape. Mazdutide is not FDA-approved in the United States. Any US-facing source claiming to prescribe it in 2026 is operating outside the regulatory framework.

What mazdutide is

Mazdutide (development designations: IBI362, LY3305677) is an investigational peptide that activates two receptors:

1. The GLP-1 receptor. The same target as semaglutide and the GLP-1 portion of tirzepatide. Effects: slowed gastric emptying, reduced appetite, improved glycemic control.
2. The glucagon receptor (GCG). The receptor activated by glucagon, the counter-regulatory hormone to insulin. Glucagon receptor agonism increases hepatic glucose output (the reason it has historically been concerning in diabetes contexts), increases basal energy expenditure, and improves hepatic lipid handling.

The dual GLP-1/GCG mechanism is the same conceptual strategy as survodutide and the triple-agonist mechanism of retatrutide minus the GIP component. The mechanistic premise is that GLP-1 reduces appetite and improves glycemic control while glucagon increases energy expenditure and supports hepatic lipid clearance, with the trade-off that glucagon agonism must be calibrated to avoid unfavorable glycemic effects.

The differentiation from survodutide is at the molecular level — different developers, different molecular structures, different pharmacokinetic profiles, different clinical programs. The two molecules will eventually be compared head-to-head in real prescribing experience but not in trial data, since each program runs independently against placebo or class-comparator controls.

What the trials have shown

Mazdutide's clinical program is split between two regulatory contexts. The Chinese program has produced phase 3 readouts and Chinese regulatory approval. The US program is in late-stage development.

Chinese phase 3 obesity (GLORY-1, GLORY-2 program). Reported mean body-weight reductions in the 14% to 18% range at the higher doses tested over the trial duration in Chinese populations with overweight or obesity. Placebo response was small. Tolerability profile was qualitatively similar to other GLP-1-class agents — gastrointestinal events predominantly during dose escalation. Glycemic effects were favorable; cardiovascular signals were within expected ranges for the class.

Chinese phase 3 type 2 diabetes (DREAM-1 program). A1c reductions in the range expected for late-stage GLP-1-class agents, with weight loss as a secondary endpoint tracking with the obesity program data.

US clinical program. Phase 2 data in US-relevant populations is publicly available; phase 3 trials enrolling US patients are in flight. The US approval pathway requires trial data in the US-relevant patient population for FDA submission.

MASH program. A separate clinical track addresses metabolic dysfunction-associated steatohepatitis. The dual GLP-1/glucagon mechanism is hypothesized to be particularly relevant in MASH because of the hepatic lipid-handling effects of glucagon agonism. MASH-specific endpoints (histology, fibrosis stage, biomarker readouts) require their own trial design and will produce their own readouts.

The headline takeaway: mazdutide is a competitive late-stage GLP-1-class compound with confirmed phase 3 efficacy in one regulatory market (China), in late-stage US development, with MASH-specific readouts separately in flight.

Where the US regulatory state stands as of May 2026

• US approval status: Not approved.
• Chinese approval status: Approved for chronic weight management as of 2025.
• US FDA submission: Expected in the 2026 to 2027 window depending on US phase 3 readout timing.
• Earliest plausible US decision: 2027 to 2028.
• Compounded versions in the US: None legitimately available. Mazdutide is patent-protected; any US source claiming to provide compounded mazdutide is operating outside the regulatory framework.

The Chinese approval is real. It means that mazdutide is a prescribed medication in China today. It does not mean that US patients can access it through any legitimate channel. International approval does not transfer to US prescribing rights, and importing prescribed medications from foreign markets without authorization is not a legitimate access path.

Why the dual GLP-1/glucagon mechanism is mechanistically distinct

The dominant approved dual-agonist mechanism is GLP-1/GIP (tirzepatide). The dual GLP-1/glucagon mechanism is a different bet:

GLP-1 agonism produces appetite reduction and slowed gastric emptying. This is the demand-side effect — patients eat less, food moves slower through the system.

GLP-1/GIP agonism produces a stronger version of the same demand-side effect. GIP supports glycemic control and appears to enhance the GLP-1 weight-loss signal, with possibly better tolerability than GLP-1 alone.

GLP-1/glucagon agonism produces appetite reduction plus increased energy expenditure. The glucagon component activates basal metabolic rate — the body burns more energy at rest. This is the supply-side effect: patients burn more energy independent of how much they eat. The mechanism affects body weight from both directions.

GLP-1/GIP/glucagon triple agonism (retatrutide) combines both demand-side and supply-side effects in a single molecule. This is the most efficacious mechanism in the late-stage pipeline, with phase 2 weight-loss readouts in the high-20% range.

Mazdutide and survodutide are dual GLP-1/glucagon compounds. They sit between the dual GLP-1/GIP mechanism (tirzepatide) and the triple-agonist mechanism (retatrutide). The expected positioning if approved is: stronger weight-loss effect than GLP-1 monotherapy, comparable or marginally less than GLP-1/GIP dual agonism on raw weight, possibly stronger hepatic effects than GLP-1/GIP, with the trade-off of glucagon-receptor-related cardiovascular monitoring.

What mazdutide approval would change

If mazdutide is approved in the US on the timelines suggested by current trial readouts:

1. Another late-stage GLP-1-class option. Mazdutide adds to a prescribing landscape that, by 2027-2028, will include semaglutide, tirzepatide, retatrutide (likely), MariTide (likely), CagriSema (likely), survodutide (likely), orforglipron (likely), and several others. Patients will have meaningful choice among compounds with different mechanistic profiles, dosing schedules, and tolerability fingerprints.
2. MASH-specific positioning. If the MASH-specific readouts support a hepatic-disease label, mazdutide may have a differentiated indication beyond chronic weight management. Compounds with MASH labels may have access advantages in patients whose primary clinical concern is liver disease rather than weight.
3. International precedent. Mazdutide's Chinese approval and the data underlying it provide a real-world post-marketing dataset before US approval. By the time the US decision occurs, there will be substantial population-scale safety and effectiveness data from Chinese prescribing. That accelerates US clinical comfort once approval lands.
4. Pricing dynamics. Multiple late-stage compounds approved within a few years of each other create competitive pricing pressure. Whether that translates to lower retail prices for patients depends on individual launch strategies and payer dynamics.

The competitive landscape is the most important context. Mazdutide is one of approximately a dozen compounds expected to reach FDA decisions in the 2026-2028 window. Each individual approval matters less in isolation than it would have a decade ago when the GLP-1 class had only one or two members.

TelePeptide's prescribing posture

TelePeptide will offer mazdutide only after FDA approval and only through pharmacy channels that handle the approved branded manufactured product in the US. The same posture we hold for every late-stage compound applies:

• No US prescribing of compounds approved only in foreign markets. Mazdutide's Chinese approval does not authorize US prescribing.
• No compounded versions of late-stage proprietary compounds. Compounded "mazdutide" sourced through US channels is not the approved Chinese product and is not legitimate.
• Standard of care. Investigational compounds in late-stage US development are not yet within US standard of care.

When mazdutide is approved in the US, our prescribing model is the same direct-pay transparent-pricing approach we apply to all approved compounds.

What to watch through 2026 and 2027

For patients tracking mazdutide:

1. US phase 3 readouts. Trial data in US-relevant patient populations is the basis for FDA submission. Readouts through 2026 and 2027 will determine submission timing.
2. MASH-specific readouts. Histology and fibrosis-stage endpoints will determine whether mazdutide gets a MASH label in addition to chronic weight management.
3. FDA submission. Submission triggers the review clock. Submission timing is the strongest signal of decision timing.
4. Real-world Chinese post-marketing data. As mazdutide accumulates real-world prescribing experience in China, post-marketing safety and effectiveness data accumulates. By the time the US decision occurs, the dataset will be meaningfully larger than at submission.

Bottom line

Mazdutide is a dual GLP-1/glucagon receptor agonist co-developed by Innovent and Eli Lilly, approved in China for chronic weight management and progressing through late-stage US development with FDA approval plausible in the 2027 to 2028 window. Phase 3 weight-loss data is in the 14% to 18% range, competitive with mid-tier injectable GLP-1 monotherapy. There is no legitimate US access path in 2026. Patients interested in mazdutide should track US trial readouts and continue to base current prescribing on currently US-approved compounds.